Lucid Diagnostics’ (LUCD) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a report published on Thursday,Benzinga reports. Canaccord Genuity Group currently has a $3.00 price target on the stock.

Several other equities research analysts have also issued reports on LUCD. Ascendiant Capital Markets lowered their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research note on Tuesday, September 10th. Needham & Company LLC reissued a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Thursday. Finally, Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Lucid Diagnostics currently has a consensus rating of “Buy” and an average price target of $3.69.

Lucid Diagnostics Stock Performance

Shares of LUCD opened at $0.99 on Thursday. The business’s 50-day moving average is $0.87 and its two-hundred day moving average is $0.85. The company has a market capitalization of $58.56 million, a P/E ratio of -0.87 and a beta of 1.41. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.58.

Institutional Investors Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC raised its position in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the period. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.